CytoSorbents Analyst Ratings
B. Riley Securities Reiterates Buy on CytoSorbents, Maintains $3 Price Target
Hold Rating on Cytosorbents Amid Regulatory Uncertainties and Mixed Clinical Results
CytoSorbents Analyst Ratings
CytoSorbents Analyst Ratings
Cytosorbents Financial and Clinical Study Outlook: Maintaining a Hold Rating
CytoSorbents Holds Steady With Neutral Rating Amid Clinical and Financial Reassessments
CytoSorbents Analyst Ratings
B. Riley Trims Price Target on Cytosorbents to $3 From $4, Maintains Buy Rating
Promising Financial Outlook and Potential Game-Changer Study Drive Buy Rating for Cytosorbents
CytoSorbents Analyst Ratings
Watching CytoSorbents; Hearing Zacks Small-Cap Research Sets $6 Price Target; Says CytoSorbents Reports 2nd Quarter 2023 Financial And Operating Results Which Showed Strong Product Revenue Growth And An Improved Cost Structure
CytoSorbents Analyst Ratings
H.C. Wainwright Reaffirms Their Buy Rating on Cytosorbents (CTSO)
HC Wainwright & Co. Reiterates Buy on CytoSorbents, Maintains $5.5 Price Target
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Cytosorbents (CTSO)
Cytosorbents (CTSO) Gets a Buy From H.C. Wainwright
HC Wainwright & Co. Reiterates Buy on CytoSorbents, Maintains $5.5 Price Target
HC Wainwright Adjusts Price Target on Cytosorbents to $5.50 From $9, Maintains Buy Rating
CytoSorbents Analyst Ratings